A Ochoa-Morales1, T Hernández-Mojica1, F Paz-Rodríguez2, A Jara-Prado1, Z Trujillo-De Los Santos3, M A Sánchez-Guzmán4, J L Guerrero-Camacho1, T Corona-Vázquez5, J Flores6, A Camacho-Molina1, V Rivas-Alonso5, D J Dávila-Ortiz de Montellano7. 1. Department of Genetics, National Institute of Neurology and Neurosurgery MVS, Insurgentes Sur 3877 Col, La Fama, Tlalpan 14269 CDMX, Mexico. 2. Department of Neuropsychology, National Institute of Neurology and Neurosurgery MVS, Mexico. 3. Palliative Care Program, National Institute of Neurology and Neurosurgery MVS, Mexico. 4. Violence Research Laboratory, National Institute of Neurology and Neurosurgery MVS, Mexico. 5. Clinical Laboratory of Neurodegenerative Diseases, National Institute of Neurology and Neurosurgery MVS, Mexico. 6. Clinical Laboratory of Neurodegenerative Diseases, National Institute of Neurology and Neurosurgery MVS, Mexico; ABC Neurological center, Mexico. 7. Department of Genetics, National Institute of Neurology and Neurosurgery MVS, Insurgentes Sur 3877 Col, La Fama, Tlalpan 14269 CDMX, Mexico. Electronic address: djdodem@gmail.com.
Abstract
OBJECTIVE: The aim of this work was to evaluate the quality of life of patients with multiple sclerosis and its association with depressive symptoms and physical health. METHOD: A total of 117 patients clinically diagnosed with Multiple Sclerosis (MS) were studied. The MSQOL-54 scale was applied. The depressive symptoms were assessed using the Beck Depression Inventory (BDI), while degree of physical disability was evaluated with the EDSS (Expanded Disability Status Scale). The results of these last two instruments were associated with MSQOL-54 to determine its influence on the perception of quality of life. RESULTS: We evaluated 65 women (56%) and 52 men (44%), with a mean age of 35 years, a mean age of 27 years at the time of diagnosis, and a mean evolution of 8 years. 88% of the patients showed the relapsing-remitting subtype; 42% had paid employment; 29% of the studied patients required help to perform daily activities; 75% took disease-modifying medications. They obtained on average a score of 3.62 ± 2.30 on the EDSS and 11.5 ± 9.21 on the BDI. The general average in MSQOL-54 was 64.67 ± 17.52. CONCLUSIONS: Quality of life, in patients with multiple sclerosis is an issue that worries health personnel, it is essential to implement strategies for reducing the impact of the disease on patients' lives, mainly through the application of programs aimed to decrees depression and improve social support.
OBJECTIVE: The aim of this work was to evaluate the quality of life of patients with multiple sclerosis and its association with depressive symptoms and physical health. METHOD: A total of 117 patients clinically diagnosed with Multiple Sclerosis (MS) were studied. The MSQOL-54 scale was applied. The depressive symptoms were assessed using the Beck Depression Inventory (BDI), while degree of physical disability was evaluated with the EDSS (Expanded Disability Status Scale). The results of these last two instruments were associated with MSQOL-54 to determine its influence on the perception of quality of life. RESULTS: We evaluated 65 women (56%) and 52 men (44%), with a mean age of 35 years, a mean age of 27 years at the time of diagnosis, and a mean evolution of 8 years. 88% of the patients showed the relapsing-remitting subtype; 42% had paid employment; 29% of the studied patients required help to perform daily activities; 75% took disease-modifying medications. They obtained on average a score of 3.62 ± 2.30 on the EDSS and 11.5 ± 9.21 on the BDI. The general average in MSQOL-54 was 64.67 ± 17.52. CONCLUSIONS: Quality of life, in patients with multiple sclerosis is an issue that worries health personnel, it is essential to implement strategies for reducing the impact of the disease on patients' lives, mainly through the application of programs aimed to decrees depression and improve social support.
Authors: Antonio Carotenuto; Laura De Giglio; Alessandro Chiodi; Maria Petracca; Laura Rosa; Maurizio Bianchi; Ilaria Ferrante; Francesca Lauro; Marcello Moccia; Antonio Ianniello; Carlo Pozzilli; Vincenzo Brescia Morra; Roberta Lanzillo Journal: Neurol Sci Date: 2020-11-21 Impact factor: 3.307
Authors: Cristina García-Muñoz; María Jesús Casuso-Holgado; Juan Carlos Hernández-Rodríguez; Elena Pinero-Pinto; Rocío Palomo-Carrión; María-Dolores Cortés-Vega Journal: BMJ Open Date: 2021-11-22 Impact factor: 2.692
Authors: Ana Myriam Lavín-Pérez; Daniel Collado-Mateo; Alejandro Caña-Pino; Santos Villafaina; Jose Alberto Parraca; María Dolores Apolo-Arenas Journal: Evid Based Complement Alternat Med Date: 2022-04-27 Impact factor: 2.650
Authors: Robert Ślusarz; Joanna Olkiewicz; Robert Bonek; Karolina Filipska; Monika Biercewicz; Adam Wiśniewski Journal: Int J Med Sci Date: 2021-08-27 Impact factor: 3.738